Election 2026

The November 3 election will reshape legislatures. Stay current on every seat, staff, and committee change with GovBuddy.

Stay Current
Home/Bills/A 1248New York · 2025–2026 Legislative Session
Assembly BillPassed first house

A 1248: Prohibits the knowing sale, offer for sale, or delivery of xylazine to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

New York · Assembly · 2025–2026 Legislative Session · last verified March 18, 2026

What A 1248 does, verified March 18, 2026

The bill aims to prohibit the sale, offer for sale, or delivery of xylazine in New York State. Xylazine is a pharmaceutical drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals. To sell xylazine, businesses must prove its intended use for institutional, veterinary, or scientific purposes. Individuals under the age of 21 cannot purchase xylazine without government-issued identification. Businesses must retain sales records, proof of age, and proof of use for at least five years. Violating the provisions of this section can result in a civil penalty of up to $3,000 for a first violation and $6,500 for subsequent violations, with all funds collected going to the New York State drug treatment and public education fund.

Bill journey
✓IntroducedComplete
✓In CommitteeComplete
✓First Chamber FloorComplete
4Second ChamberCurrent
5GovernorPending
6ChapteredPending
Last action: REFERRED TO CONSUMER PROTECTION (2026-03-10)Alert me
Author and sponsors
Full contact details, staff, and committees with Connect, $16/moUnlock
Coauthors
John ZaccaroGeorge AlvarezCharles LavineManny De Los SantosTony SimonePhara Souffrant ForrestMaryJane ShimskyNikki LucasBrian CunninghamCatalina CruzJo Anne SimonNader Sayegh
Recent actions28 total · showing 5
Mar. 10, 2026REFERRED TO CONSUMER PROTECTION
Mar. 10, 2026delivered to senate
Mar. 10, 2026passed assembly
Jan. 12, 2026amended on third reading (t) 1248c
Jan. 07, 2026ordered to third reading cal.44
Full action history, 23 earlier actionsConnect Plus
Latest bill textIntroduced version, January 9, 2025 · 457 words
  
  STATE OF NEW YORK ________________________________________________________________________ 1248 2025-2026 Regular Sessions  IN ASSEMBLY January 9, 2025 ___________ Introduced by M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, DE LOS SANTOS, SIMONE, FORREST, SHIMSKY, LUCAS, CUNNINGHAM, CRUZ, SIMON, SAYEGH, EPSTEIN, BICHOTTE HERMELYN, BORES, K. BROWN, CHANG, GIGLIO, PIROZZOLO, DeSTEFANO -- read once and referred to the Committee on Consumer Affairs and Protection AN ACT to amend the general business law, in relation to prohibiting the sale of xylazine The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The general business law is amended by adding a new section 2 392-k to read as follows: 3 § 392-k. Sale of xylazine. 1. For purposes of this section, the term 4 "xylazine" shall mean a pharmaceutical drug used for sedation, anes- 5 thesia, muscle relaxation, and analgesia in animals such as horses, 6 cattle, and other non-human mammals. 7 2. No corporation, partnership, limited liability company, firm, 8 online platform, or any other business entity doing business within this 9 state shall knowingly sell, offer for sale, or deliver xylazine to indi- 10 viduals without proof of its intended use for institutional, veterinary, 11 or scientific purposes. 12 3. No corporation, partnership, limited liability company, firm, 13 online platform, or other business entity doing business within this 14 state shall knowingly sell, offer for sale, or deliver xylazine to indi- 15 viduals under the age of twenty-one. 16 4. Any corporation, partnership, limited liability company, firm, 17 online platform or other business entity doing business within this 18 state which knowingly sells, offers for sale, or distributes xylazine, 19 shall require and retain sales records, proof of age, and proof of use 20 from all purchasers. 21 5. Any corporation, partnership, limited liability company, firm, 22 online platform, or other business entity doing business within this EXPLANATION--Matter in italics (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD02623-01-5 

 A. 1248 2 1 state that violates the provisions of this section by knowingly selling, 2 offering for sale, or delivering xylazine shall be subject to a civil 3 penalty of not more than three thousand dollars for a first violation, 4 and sixty-five hundred dollars for each subsequent violation, recovera- 5 ble in an action by the attorney general of the state of New York. All 6 funds collected or received by the state from civil penalties imposed 7 under this section shall be deposited in the New York state drug treat- 8 ment and public education fund established pursuant to section ninety- 9 nine-jj of the state finance law. 10 § 2. This act shall take effect immediately. 

Text of A 1248 as introduced, from the official record. Connect Plus keeps every version and highlights what changed.Compare versions
GovBuddy Demo

See how GovBuddy fits your team.

Share a few details and our team will follow up with a focused walkthrough.